XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Segment and Geographic Information (Tables)
9 Months Ended
Sep. 29, 2024
Industry And Geographic Information [Abstract]  
Revenue from External Customers by Geographic Areas
Total revenues by reportable segment are as follows:
Three Months EndedNine Months Ended
(In millions)September 29, 2024October 1,
2023
September 29, 2024October 1,
2023
North America$436.2 $465.2 $1,220.2 $1,426.8 
EMEA84.0 74.5 249.9 236.4 
China80.4 81.1 238.1 233.0 
Other126.5 123.2 366.9 359.0 
Total revenues$727.1 $744.0 $2,075.1 $2,255.2 
Schedule of Segment Reporting Information, by Segment
The following table sets forth Adjusted EBITDA by segment and the reconciliations to Loss before income taxes for the three and nine months ended September 29, 2024 and October 1, 2023:
Three Months EndedNine Months Ended
(In millions)September 29, 2024October 1,
2023
September 29, 2024October 1,
2023
North America$233.0 $253.4 $625.7 $708.1 
EMEA6.7 10.2 30.9 22.7 
China36.9 37.3 97.4 96.0 
Other31.7 31.2 97.8 89.3 
Total segment Adjusted EBITDA308.3 332.1 851.8 916.1 
Corporate (1)
(137.6)(162.9)(459.2)(388.3)
Depreciation and amortization(113.1)(113.1)(344.1)(341.8)
Interest expense, net(42.9)(37.7)(122.9)(110.9)
Integration related costs(36.8)(26.5)(90.3)(80.4)
Goodwill impairment charge— — (1,743.9)— 
Asset impairment charge— (2.2)(56.9)(3.2)
Amortization of deferred cloud computing implementation costs(4.7)(2.8)(10.6)(5.9)
EU medical device regulation transition costs (2)
(0.4)(0.4)(1.5)(1.9)
Loss on investments— (1.0)— (1.2)
Employee compensation charges— — (5.6)— 
Credit Agreement amendment fees — — (4.0)— 
Tax indemnification income— 0.1 — 0.2 
Other adjustments(1.6)(1.1)(3.4)(2.6)
Loss before income taxes$(28.8)$(15.5)$(1,990.6)$(19.9)
(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
(2) Represents incremental consulting costs and R&D manufacturing site costs to align compliance of the Company’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.